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Tuberculosis-Related Deaths 
within a Well-Functioning DOTS 
Control Program
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Maria Cecilia García-Sancho,‡ Leticia Ferreyra-Reyes,* Manuel Palacios-Martínez,* 
Javier Fuentes,§ Midori Kato-Maeda,† Miriam Bobadilla,† 
Peter Small,¶ and José Sifuentes-Osornio,† 
To describe the molecular epidemiology of tuberculosis (TB)-related deaths in a well-managed program in
a low-HIV area, we analyzed data from a cohort of 454 pulmonary TB patients recruited between March
1995 and October 2000 in southern Mexico. Patients who were sputum acid-fast bacillus smear positive
underwent clinical and mycobacteriologic evaluation (isolation, identification, drug-susceptibility testing,
and IS6110-based genotyping and spoligotyping) and received treatment from the local directly observed
treatment strategy (DOTS) program. After an average of 2.3 years of follow-up, death was higher for clus-
tered cases (28.6 vs. 7%, p=0.01). Cox analysis revealed that TB-related mortality hazard ratios included
treatment default (8.9), multidrug resistance (5.7), recently transmitted TB (4.1), weight loss (3.9), and hav-
ing less than 6 years of formal education (2). In this community, TB is associated with high mortality rates. 
n both humanistic and economic terms, the cost of deaths
due to tuberculosis (TB) is staggering. In 1990 alone,
approximately 2.5 million people died of TB, accounting for
>25% of avoidable adult deaths in the developing world (1,2).
Directly observed treatment strategy (DOTS), a comprehen-
sive approach to TB control, is one of the most cost-effective
health interventions available (3,4). In the context of a well
functioning DOTS program, cure rates in excess of 80% can
be expected. While these outcomes are assumed to decrease
mortality rates, the detailed epidemiology of deaths in a well-
functioning DOTS program by using modern molecular tech-
niques has not been described.
Since 1995, we have conducted a population-based molec-
ular epidemiologic study of TB in a health district in southern
Mexico. Previous reports have documented the TB control
program approaches World Health Organization benchmarks
(5) and drug resistance is considerable and has an important
negative impact on treatment outcomes (6). We now report the
short- and long- term mortality rates due to TB in this cohort
of TB patients. These data suggest that, as has been described
with other diseases, excess mortality may persist for months or
years after treatment completion, default, or failure (7,8). 
Methods
The study site, described previously (5,6,9), is located in a
predominantly urban region in the Orizaba Health Jurisdiction
in the state of Veracruz, which encompasses 134 square km
and has a population of 284,728 (10). The incidence rate of TB
during the year 2000 for the state was higher than that for the
nation (28.0 vs. 15.9 per 100,000 inhabitants) (11).
Community-based screening of chronic coughers (>2
weeks) was performed from March 1995 to October 2000.
Patients with positive AFB sputum smears underwent epide-
miologic, clinical (standardized questionnaire, physical exam,
chest x-ray, and HIV test), and mycobacteriologic evaluation.
Treatment was provided in accordance with official norms
(12,13). Treatment outcomes were classified as previously
described (6). Annual follow-up was performed for treatment
outcome and vital status. Deaths were confirmed with death
certificates. A close caregiver was interviewed to elicit signs
and symptoms of the terminal illness and “probable cause of
death” was assigned by two of the authors (JF, LF). Informed
consent was obtained from participants. The study was
approved by the appropriate institutional review boards.
Microbiologic Evaluation
Mycobacterial culture, identification, and susceptibility
testing were performed on sputa from each enrolled patient. In
brief, unconcentrated sputum was spread onto Lowenstein-
Jensen media (DIFCO, Detroit, MI) at the local laboratory, and
the remaining sputum was frozen at –70°C. The tubes were
examined on a weekly basis until growth was detected. Cul-
tures were reported as negative if no growth occurred after 8
weeks. Cultures with visible growth were forwarded to the
department of Mycobacteriology at the Instituto de Diagnos-
tico y Referencia Epidemiológicos (March 1995 to December
1997) or to the Clinical Microbiology Laboratory of the Insti-
tuto Nacional de Ciencias Médicas y Nutrición (INCMNSZ)
(January 1998 to October 2000) for definitive biochemical
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identification at the species level (14,15). The frozen sputum
sample was processed if the first sample was contaminated or
had no growth. Identification and drug susceptibility tests
were carried out using conventional methods and the
BACTEC system (Becton Dickinson, Cockeysville, MD). 
Mycobacterium tuberculosis Fingerprinting
Mycobacteria isolated from study patients were genotyped
at Stanford University from March 1995 to February 1997 and
at INCMNSZ from March 1997 to October 2000 with the
internationally standardized IS6110-based restriction fragment
length polymorphism (RFLP) technique and compared by
using a computer-assisted visual approach (Bioimage AQ-1
analyzer and Molecular Fingerprinting Analyzer, version 2.0)
(16,17). Isolates with identical IS6110 fingerprints that con-
tained five or fewer hybridizing bands underwent spoligotyp-
ing at INCMNSZ as described (18,19). To assess transmission
of M tuberculosis that rapidly progressed to disease, we estab-
lished a 1-year period for defining clustering as described (20).
Cases were considered “clustered” if two or more isolates
from different patients were identified within a year that had 1)
six or more IS6110 bands in an identical pattern, or 2) five or
fewer bands with identical IS6110 fingerprints and matching
spoligotypes. The first patient diagnosed in each cluster and
those with unique fingerprints were classified as having reacti-
vated disease.
Analysis
Deaths were attributed to TB based on the death certificate
(TB listed as the cause of death), interview of close caregiver
(TB identified as probable cause of death), and active TB at
the time of death (positive AFB smear after last treatment or
during treatment if the patient did not complete treatment per-
formed <6 months before death). A patient’s death was attrib-
uted to TB if two or more of these conditions were met.
Bivariate and multivariate analyses were performed to
describe association between sociodemographic (age, sex,
household characteristics, occupation, ethnicity, years of for-
mal education, place of residence, and social security), behav-
ioral (usage of drugs and alcohol, and previous incarceration),
clinical (previous diagnosis of TB; other associated diseases,
previous hospitalizations; HIV infection, duration of symp-
toms previous to diagnosis; time elapsed between diagnosis
and initiation of treatment and between initiation of treatment
and smear conversion; and symptoms such as cough, hemop-
tysis, fever, night sweats, weight loss, and general malaise),
bacteriologic (number of bacilli per microscopic field, drug
resistance, RFLP, or spoligotype pattern), therapeutic (compli-
ance, treatment outcome, and retreatment) variables, and death
due to TB and other causes. Survival analyses included
Kaplan-Meier curves and Cox proportional hazards model for
TB and non-TB–related deaths using as reference time the
period elapsed from diagnosis. Variables were entered into the
models according to their statistical significance in univariate
analysis and their biological relevance. The percentage of pop-
ulation attributable risk was calculated for variables that were
included in the final model (21). DBASE IV and STATA 5.0
programs were used for data analysis (22). 
Results
During the study period, 454 patients were diagnosed with
pulmonary TB. Most patients were men (270 [59.5%] of 454)
and the median age was 42 years (range 12–97 years). Most
came from lower socioeconomic status as indicated by house-
hold characteristics, formal years of education, and occupa-
tion. Of 438 patients, 74 (17%) lived in households with
earthen floor, 214 (49.3%) of 434 had no access to potable
water within the household, 293 (65.4%) of 448 had <6 years
of formal education, and 104 (23.4%) of 445 were manual
workers. The prevalence of HIV was 2.1% (9 of 429), com-
bined resistance to isoniazid and rifampin was seen in 26
(6.7%) of 388 patients, and other resistance patterns in an
additional 61 (15.7%) of 388. One hundred fifty-one (37%) of
413 patients had chest radiographs with evidence of pulmo-
nary cavitation, and 72 (17.4%) of 413 patients had interstitial
pulmonary infiltrates. Median time from initiation of symp-
toms to treatment was 101 days (range 3–2,307 days), median
time from diagnosis to initiation of treatment was 5 days
(range 0–594 days), and median time for sputum conversion
was 42 days (range 15–1,228 days). 
Treatment and Follow-Up
Of 11 patients who refused treatment, 4 died. Of 443 initi-
ating treatment, 75.4% initiated treatment <10 days after diag-
nosis; 96.5% received supervised treatment. Outcomes for
patients were as follows: 357 (80.6%) were cured of whom
314 (70.9%) were bacteriologically confirmed, 41 (9.3%)
defaulted, and 20 (4.5%) failed treatment; 16 (3.6%) died dur-
ing treatment, and 9 (2%) transferred out of study area.
Patients were tracked for a median of 839 days (range 3–
2,402). Sixty-one additional patients died during follow-up
after treatment. Death was due to TB in 34 (41.9%) of 81
instances; 2 deaths were in patients who did not receive treat-
ment, 11 in patients receiving treatment, and 21 after treat-
ment. Tuberculosis mortality rates were higher during
treatment versus after treatment (1.3/10,000 days vs. 0.7/
10,000 days, p<0.01). Crude comparison of sociodemo-
graphic, bacteriologic, and clinical characteristics of patients
who died from TB or from other causes and surviving patients
are shown in Table 1. Patients who died from TB had a higher
probability of having been treated for a previous TB episode,
showed more severe clinical symptoms, and had drug-resistant
isolates. Less frequently they had other coexisting chronic
conditions, such as HIV infection or hepatic cirrhosis. The
patients who died from TB also had longer delays before diag-
nosis, treatment, and sputum conversion. These patients had
higher probabilities of default, failure, and having subsequent
TB episodes. The most common non-TB causes of death
included diabetes (12), cirrhosis and other liver diseases (9),
AIDS (6), cancer (2), and cardiovascular diseases (3). KaplanEmerging Infectious Diseases  •  Vol. 8, No. 11, November 2002 1329
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Meier survival probabilities from TB deaths were 97.3% after
the first 6 months, 95.8% after 1 year, 93.7% after 2 years, and
91% after 3 years.
RFLP and Spoligotyping Results
M. tuberculosis culture, drug test, and IS6110 RFLP and
spoligotyping were available for 326 (72%) isolates. Compari-
son of patients whose isolates were available for genotyping to
those whose isolates were unavailable indicated that patients
for whom fingerprint analysis was not performed had a higher
probability of being of native origin in Mexico (30 [24.2%] of
124 vs. 39 [12%] of 324, p= 0.001) and of living in house-
holds with earthen floor (31 [25.8%] of 120 vs. 43 [13.5%] of
318, p=0.002). Forty (12.3%) of the 326 evaluated cases were
Table 1. Sociodemographic, clinical, bacteriologic, and therapeutic characteristics of smear-positive pulmonary tuberculosis (TB) patients accord-
ing to cause of death, Orizaba, Veracruz, 1995–2000
Variables
Died from TB
(n=34) (%)
Died from other causes
(n=47) (%)
Survived
(n=373) (%) p valuea
Sociodemographic
Median age (range) 30 (24–73) 47 (22–70) 40.5 (12–82) 0.05
Men 52.9 76.6 57.9 0.04
Indigenous origin  20.6 4.3 16.1 0.07
<6 years formal education  73.5 76.6 62.2 0.02
Rural and industrial workers 11.8 25.5 23.6 0.2
Previous imprisonment  14.7 34.0 27.9 0.2
Previous TB treatment 47.1 34.0 14.2 <0.0001
Previous hospitalization  58.8 51.1 45.6 0.2
Residence in shelters 5.9 10.6 5.1 0.3
Alcohol use  38.2 66.0 43.7 0.005
Household crowding 47.1 27.7 37.5 0.2
Household with earthen floor 20.6 10.6 16.6 0.4
Clinical 
HIV infection  8.8 10.6 .3 <0.0001
Hepatic cirrhosis  0 6.4 1.3 0.06
Body mass index (<18) 47.1 27.7 20.4 <0.0001
Hemoptysis 26.5 38.3 37.8 0.5
Fever 44.1 61.7 44 0.04
Night sweats  58.8 59.6 57.6 0.2
Weight loss (>15 %) 47.1 46.8 29.2 0.002
Radiologic nodes  5.9 6.4 7.0 0.9
Cavities 44.1 25.5 33.2 0.2
Median time interval between initiation of symptoms
and treatment (range in days)
17 (1–212) 8 (0–158) 5 (0–322) 0.004
Median time interval between diagnosis and treatment 
(range in days)
141.5 (78–991) 126 (4–439) 99.5 (4–1,723) 0.01
Bacteriologic
Resistance to isoniazid and rifampin  29.4 17.0 2.1 <0.0001
Other resistance 11.8 19.1 12.9 0.2
<10 bacilli per 100 fields  79.4 87.2 86.1 0.5
Median time interval between treatment and sputum 
conversion (range in days)
95 (35–530)  44 (19–182) 42.5 (15–348) 0.03
Treatment outcome
Cure 5.9 61.7 87.4 <0.0001
Failure 20.6 10.6 2.1 <0.0001
Default 32.4 10.6 6.7 <0.0001
Retreatment 17.6 23.4 5.4 <0.0001
aChi square test, analysis of variance test.RESEARCH
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in clusters. The frequency of being members of clusters of
recently transmitted disease was higher among patients dying
from TB than among those dying from other causes or surviv-
ing (8 [28.5%] of 28 patients who died from TB vs. 32
[10.7%] of 298 patients who died from other causes and survi-
vors, p=0.01).
Factors Associated with Mortality Rates
Predictors of death due to TB by Cox regression analysis
included treatment default, resistance to isoniazid and
rifampin, and recently transmitted TB controlling for time of
occurrence of death, weight loss >15%, and years of formal
education (Table 2). The effect was not modified when gender,
age, HIV infection, crowding in the household, household
characteristics, occupation, ethnicity, previous treatment,
delay in seeking treatment, specific symptoms, type of radio-
logic lesions, and other kinds of diseases were introduced into
the model. 
After controlling for age, predictors of non-TB death
included HIV-infection, hepatic cirrhosis, and weight loss.
Recently transmitted TB was not associated with other causes
of death (Table 2). 
The proportion of death due to TB and to other causes
attributable to the different categories of risk factors is shown
in Table 2. In the study population, 60% of deaths due to TB
were attributable to drug resistance and treatment default. 
Patients with recently transmitted disease had a lower proba-
bility of survival compared with patients with reactivated dis-
ease (p=0.007) (Figure). When causes of death were analyzed
according to genotype, we found that TB was the cause of death
in 8 (20%) of 40 patients with recently transmitted disease and
in 20 (7%) of 286 patients with reactivated disease (p=0.01).
Sensitivity Analysis
Analysis of the distribution of the time between diagnosis
dates of successive matching fingerprints indicated that 49.4%
(95% confidence interval [CI] 44% to 54%) of all isolates with
matching fingerprints patterns were identified within 1 year.
When the interval was modified to 6, 18, 24, 30, and 36
months, we found that the proportion of clustered cases
increased (8.3%, 13.8%, 13.8%, 14.4%, and 14.7%, respec-
tively), (χ 2 trend, p=0.02). The association between clustered
cases and death due to TB continued to be positive for each of
the other definitions of interval for clustering: 3.6 (1.1 to 10.5),
p=0.01; 2.8 (1.0 to 7.3), p=0.03; 2.8 (1.0 to 7.3), p=0.03; 2.7
(0.9 to 6.8), p=0.04; and 2.6 (0.9 to 6.6) p=0.04.
Discussion
This study describes high mortality rates from TB in a
cohort of pulmonary TB patients who resided in an area with
a low rate of HIV infection and were treated in the context of
a well-functioning DOTS program. Patients were followed
for an average of 2.3 years after diagnosis. Tuberculosis was
associated with high rates of deaths both during treatment
and after treatment completion, default, or failure. The main
independent risk factors for death due to TB were treatment
default and being infected with multidrug-resistant M. tuber-
culosis. Additionally, data indicate that cases due to ongoing
transmission of TB may have higher mortality rates than
cases due to reactivation of latent disease. These results sug-
gest that current techniques underestimate death associated
with TB and provide further impetus not only to treat but also
to prevent TB. 
Case completion rates are the standard by which the effec-
tiveness of DOTS-based treatment programs are judged. A
large body of evidence collected under diverse settings dem-
onstrates completion rates of 81% and cure rates of 73% (23).
The epidemiology of death in these programs is less well stud-
ied. Studies performed in HIV-endemic settings constitute an
exception as the high rate of deaths occurring while patients
are still on antituberculous therapy are cited as an impediment
to achieving desired cure rates (24). 
Table 2. Population attributable-risk percent and hazard ratios for death among smear-positive tuberculosis (TB) patients, Orizaba, Veracruz, 
1995–2000a
Variables Population attributable risk (%) Adjusted hazard ratio 95% CI p valueb
Death due to TBc
Treatment default 28.7 8.9 3.3 to 24.4 <0.0001
Resistance to isoniazid and rifampin  25.9 5.7 2.0 to 16.3 <0.001
Clustered 18.8 4.1 1.6 to 10.0 0.002
Weight loss (>15%) - 3.9 1.5 to 10.9 0.007
Formal education <6 yr - 1.8 0.6 to 5.2 0.3
Death due to other causes
HIV/AIDS 11.1 33.1 11.4 to 95.4 <0.0001
Hepatic cirrhosis  6.6 5.7 1.6 to 19.7 0.006
Weight loss (>15% ) - 3.3 1.6 to 6.7 0.001
Age (yrs) - 1.02 0.99 to 1.04 0.07
aCI, confidence interval; -, not applicable.
bCox proportional hazards model.
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Our study reports TB mortality rates both during and after
treatment completion, default, or failure. Of the 443 patients
who were started on therapy, 16 died before completing ther-
apy. This frequency (3.6%) compares favorably to that
reported in other studies (4% in the Gambia [25], 15% in
Bolivia [26], 25% in Malawi [27], and 28% in India [28]).
However, in contrast to previous reports, we had a median of
833 days of follow-up after the completion of therapy, during
which 21 additional patients (4.6%) died of TB, comparable
with reports from the 1960s and 1970s (29). This mortality
rate exceeds that expected according to age-adjusted state
mortality statistics (30).
Although not novel, the risk factors for death due to TB
identified in this cohort are noteworthy; these findings suggest
that, even in a high-quality TB control program, additional
efforts could yield important benefits. Treatment default has
been previously described as associated with higher mortality
rates in Mexico (31) and elsewhere (32,33). Concerted efforts
to further reduce default may disproportionately decrease
deaths. We also found that drug resistance, and particularly
multidrug resistance, are associated with death (6,14,34).
Although the most appropriate strategy for managing drug-
resistant TB is debated, these data provide additional impetus
for evaluating novel approaches, such as those recently intro-
duced in Mexico, for managing drug-resistant TB (13,35). We
estimate that 60% of deaths due to TB in this setting were
attributable to treatment default and multidrug-resistance.
Additional studies are needed to quantitate the presumably
greater mortality rates that result from default and drug resis-
tance in other settings. 
Although relatively uncommon in this setting, HIV was
associated with a high overall mortality rate. Most of these
deaths were due to non-TB–related death. HIV/AIDS was the
main predictor for non-TB deaths in this cohort. In our study,
eight of the nine HIV-seropositive persons died, three of them
a year or more after completing antituberculous therapy. Sev-
eral studies have demonstrated excess mortality rates after suc-
cessful TB treatment in HIV-infected patients (24,36,37); the
high rates have been attributed to HIV-related disease (38).
These data emphasize the need to improve integration of qual-
ity treatment for both TB- and HIV-infected persons in popula-
tions that suffer from both diseases. 
The most striking finding of the molecular epidemiologic
component of this study is the association between clustering,
which we interpret as indicative of recently transmitted dis-
ease, and TB-related death. Death due to TB was significantly
more common among those who had recently transmitted dis-
ease than those with reactivated disease (28.6% vs. 7%,
p=0.01). This association was independent of treatment
default, multidrug resistance, time of occurrence of death,
weight loss, and years of formal education. Furthermore, the
effect was not modified when other variables indicative of
sociodemographic level (such as occupation, characteristics of
the household, or ethnicity) or clinical variables indicating
other diseases, including HIV infection were introduced in the
model. Inferring causality from such associations is difficult, it
seems biologically implausible that being more likely to die
made people more likely to acquire recently transmitted TB. A
more plausible explanation is that rapidly progressing to dis-
ease contributes to deterioration of the health of these patients
and thus increases their likelihood of death. The phenomenon
is well described for other diseases such as measles. However,
why this would be more pronounced for recently transmitted
disease is unclear. 
The association between clustering and death could be
spurious because of limitations in molecular or conventional
epidemiology. The validity of clustering as a proxy for recent
transmission might be challenged by the fact that we did not
perform fingerprint analysis on all isolates (39). Comparison
between patients whose isolates were genotyped and those
whose isolates were not genotyped showed that results of this
study may not be generalizable to indigenous or lower socio-
economic groups. Our selection of the time interval allowed us
to consider TB that was transmitted very recently and pro-
gressed to disease. The validity of using a 1-year interval was
confirmed with the sensitivity analysis using different time
periods (6, 18, 24, 30, and 36 months) as association between
clustered cases and death persisted, despite modification of the
time interval and by the fact that almost 50% of isolates with
matching DNA fingerprint patterns occurred within 1 year of
identification of the previous case. Conventional epidemio-
logic approaches to studying the cause of death are difficult.
Death certificate data are notoriously unreliable, and whether
patients died of TB or other causes is not certain (40). There-
fore, we added other criteria that included the interview of a
close caregiver and activity of TB at the time of death to vali-
date our definition of death due to TB. The cause-of-death pro-
file derived from interview of a close caregiver has been
demonstrated to be useful for planning purposes (41). We con-
sider that this definition adequately identified TB-related death
Figure. Estimated survival of smear-positive pulmonary tuberculosis
patients according to clustered or unique fingerprint pattern in a low
HIV-prevalence community (p=0.01).RESEARCH
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as characteristics of patients dying from TB differed from
patients dying from other causes in several important aspects
(drug resistance, coexisting chronic conditions, and clinical
severity) and allowed the identification of different risk factors
for TB-related death and for death due to other causes.
If confirmed in other settings, the conclusions of this study
have important implications for control programs. Most
importantly, given that current surveillance data are collected
at the conclusion of therapy, this method probably underesti-
mates the true impact of TB on a population’s death. Given the
increasing role of cost-efficacy modeling in setting health-care
priorities, this oversight has important consequences. In addi-
tion, if recently acquired TB exhorts a greater mortality rate
than that due to reactivated infection, the importance of inter-
rupting TB transmission is further elevated. 
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